RYTM RSI Chart
Last 7 days
-2.6%
Last 30 days
-3.7%
Last 90 days
-7.2%
Trailing 12 Months
87.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 33.6M | 43.8M | 62.0M | 77.4M |
2022 | 8.3M | 13.4M | 18.5M | 23.6M |
2021 | 0 | 0 | 0 | 3.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 14, 2024 | mazabraud yann | sold | - | - | -10,375 | evp, head of international |
Apr 02, 2024 | german christopher paul | sold | -15,367 | 41.76 | -368 | corporate controller & cao |
Mar 21, 2024 | shulman joseph | sold | -735,600 | 40.34 | -18,235 | chief technical officer |
Mar 20, 2024 | german christopher paul | acquired | - | - | 1,163 | corporate controller & cao |
Mar 20, 2024 | lee jennifer kayden | sold | -707,005 | 38.7719 | -18,235 | evp, head of north america |
Mar 19, 2024 | shulman joseph | sold | -608,498 | 39.22 | -15,515 | chief technical officer |
Mar 19, 2024 | smith hunter c | sold | -608,498 | 39.22 | -15,515 | chief financial officer |
Mar 19, 2024 | mazabraud yann | sold | -627,520 | 39.22 | -16,000 | evp, head of international |
Mar 19, 2024 | cramer pamela j. | sold | -608,498 | 39.22 | -15,515 | chief human resources officer |
Mar 19, 2024 | meeker david p | sold | -1,784,270 | 39.22 | -45,494 | president and ceo |
Which funds bought or sold RYTM recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 22, 2024 | MetLife Investment Management, LLC | unchanged | - | 625,049 | 1,246,840 | 0.01% |
Apr 19, 2024 | Cutler Group LLC / CA | added | 120 | 25,000 | 47,000 | 0.01% |
Apr 19, 2024 | ZRC WEALTH MANAGEMENT, LLC | added | 392 | 76,234 | 85,404 | 0.04% |
Apr 18, 2024 | Allspring Global Investments Holdings, LLC | new | - | 867 | 867 | -% |
Apr 17, 2024 | Hennion & Walsh Asset Management, Inc. | added | 30.37 | 701,713 | 3,768,280 | 0.20% |
Apr 16, 2024 | Stratos Wealth Partners, LTD. | sold off | -100 | -333,926 | - | -% |
Apr 15, 2024 | Concurrent Investment Advisors, LLC | new | - | 343,488 | 343,488 | 0.02% |
Apr 05, 2024 | LOS ANGELES CAPITAL MANAGEMENT LLC | sold off | -100 | -486,960 | - | -% |
Apr 05, 2024 | GAMMA Investing LLC | added | 115 | 640 | 1,213 | -% |
Apr 05, 2024 | CWM, LLC | added | 95.17 | 8,000 | 18,000 | -% |
Unveiling Rhythm Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Rhythm Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.74 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.4B | 1.8B | -41.72 | 10.05 | ||||
BMRN | 16.9B | 2.4B | 100.76 | 6.98 | ||||
INCY | 11.7B | 3.7B | 19.5 | 3.15 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.87 | 14.48 | ||||
BBIO | 4.4B | - | -6.75 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.08 | 12.45 | ||||
ARWR | 3.0B | 240.7M | -9.98 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.68 | 3.85 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.31 | 4.36 | ||||
NVAX | 587.8M | 983.7M | -1.08 | 0.6 | ||||
CRBP | 396.0M | 881.7K | -8.88 | 466.16 | ||||
INO | 242.4M | 4.9M | -1.79 | 49.8 | ||||
IBIO | 6.7M | 2.1M | -0.25 | 2.14 |
Rhythm Pharmaceuticals Inc News
Income Statement (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Revenue | 7.7% | 24,234,000 | 22,504,000 | 19,221,000 | 11,469,000 | 8,790,000 | 4,284,000 | 9,066,000 | 1,498,000 | - | - | - | - |
Costs and Expenses | -1.4% | 65,501,000 | 66,457,000 | 65,825,000 | 64,000,000 | 50,893,000 | 43,551,000 | 54,162,000 | 54,189,000 | 52,806,000 | 45,268,000 | 40,706,000 | 34,433,000 |
S&GA Expenses | 6.2% | 32,375,500 | 30,475,000 | 30,046,000 | 24,634,000 | 26,317,000 | 21,938,000 | 22,328,000 | 21,449,000 | 20,996,000 | 17,507,000 | 15,465,000 | 14,518,000 |
R&D Expenses | -11.0% | 29,892,500 | 33,570,000 | 33,543,000 | 37,945,000 | 23,548,000 | 21,116,000 | 31,456,000 | 32,510,000 | 31,574,000 | 27,539,000 | 25,104,000 | 19,911,000 |
EBITDA Margin | -Infinity% | -2.00 | - | -4.00 | -5.20 | -7.40 | - | - | - | - | - | - | - |
Interest Expenses | 41.8% | 4,464,500 | 3,149,000 | 3,303,000 | 3,061,000 | - | 2,144,000 | 46,000 | - | - | - | - | - |
Income Taxes | -46.7% | 196,000 | 368,000 | - | - | - | - | - | - | - | -8,995,000 | -5,022,000 | 22,006,000 |
Earnings Before Taxes | 5.4% | -41,437,000 | -43,795,000 | - | - | -42,493,000 | -40,861,000 | - | - | -63,840,000 | - | -40,411,000 | 65,756,000 |
EBT Margin | -Infinity% | -2.18 | - | -4.14 | -5.39 | -7.66 | -3.76 | -5.20 | -8.41 | -22.07 | - | - | - |
Net Income | 5.7% | -41,633,000 | -44,163,000 | -46,703,000 | -52,179,000 | -42,493,000 | -40,861,000 | -45,001,000 | -52,764,000 | -42,866,000 | -35,107,000 | -35,389,000 | 43,750,000 |
Net Income Margin | 20.3% | -2.39 | -2.99 | -4.16 | -5.37 | -7.66 | -9.80 | -13.12 | -20.08 | -22.07 | - | - | - |
Free Cashflow | -0.4% | -29,382,000 | -29,252,000 | -41,090,000 | -36,480,000 | -33,999,000 | -47,082,000 | -38,869,000 | -53,759,000 | -40,540,000 | -40,266,000 | -32,088,000 | -33,543,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -6.1% | 333 | 354 | 310 | 346 | 382 | 390 | 278 | 285 | 330 | 356 | 388 | 422 | 187 | 215 | 243 | 274 | 309 | 178 | 211 | 237 | 260 |
Current Assets | -6.4% | 308 | 329 | 284 | 318 | 354 | 362 | 249 | 253 | 308 | 336 | 378 | 412 | 182 | 210 | 238 | 268 | 302 | 171 | 204 | 230 | 259 |
Cash Equivalents | -7.0% | 60.00 | 65.00 | 116 | 110 | 128 | 185 | 113 | 79.00 | 59.00 | 92.00 | 69.00 | 87.00 | 101 | 68.00 | 59.00 | 56.00 | 63.00 | 72.00 | 64.00 | 42.00 | 50.00 |
Inventory | 11.1% | 9.00 | 8.00 | 6.00 | 5.00 | 3.00 | - | - | - | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -13.2% | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 1.00 |
Liabilities | 4.0% | 163 | 157 | 128 | 126 | 118 | 108 | 82.00 | 49.00 | 45.00 | 34.00 | 37.00 | 41.00 | 21.00 | 19.00 | 18.00 | 21.00 | 28.00 | 28.00 | 29.00 | 16.00 | 14.00 |
Current Liabilities | 10.1% | 55.00 | 50.00 | 46.00 | 46.00 | 40.00 | 33.00 | 45.00 | 47.00 | 43.00 | 23.00 | 17.00 | 17.00 | 18.00 | 16.00 | 15.00 | 18.00 | 24.00 | 25.00 | 26.00 | 13.00 | 14.00 |
Long Term Debt | - | - | - | - | - | - | 73.00 | 34.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -14.0% | 170 | 197 | 182 | 220 | 264 | 281 | 196 | 236 | 284 | 322 | 352 | 381 | 167 | 197 | 226 | 253 | 281 | 149 | 181 | 220 | 246 |
Retained Earnings | -4.9% | -894 | -853 | -808 | -762 | -710 | -667 | -626 | -581 | -528 | -486 | -450 | -415 | -459 | -424 | -390 | -359 | -325 | -292 | -256 | -213 | -184 |
Additional Paid-In Capital | 1.3% | 1,064 | 1,051 | 991 | 982 | 974 | 949 | 823 | 818 | 813 | 808 | 803 | 797 | 626 | 621 | 616 | 613 | 606 | 441 | 438 | 434 | 431 |
Shares Outstanding | 0.6% | 59.00 | 59.00 | 57.00 | 57.00 | 57.00 | 51.00 | 50.00 | 50.00 | 50.00 | 49.00 | 49.00 | 48.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 887 | - | - | - | 188 | - | - | - | 884 | - | - | - | 828 | - | - | - | 569 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -0.5% | -29,383 | -29,251 | -41,090 | -36,433 | -34,000 | -46,987 | -38,809 | -53,632 | -40,472 | -40,160 | -31,840 | -33,531 | -29,122 | -27,031 | -29,729 | -36,098 | -32,221 | -33,605 | -25,546 | -31,378 | -20,983 |
Share Based Compensation | 0.7% | 8,674 | 8,612 | 8,891 | 6,376 | 5,287 | 4,796 | 5,137 | 4,611 | 4,676 | 5,268 | 5,669 | 5,191 | 4,257 | 4,695 | 3,028 | 5,475 | 2,924 | 3,035 | 3,272 | 2,644 | 2,023 |
Cashflow From Investing | 123.8% | 22,640 | -94,960 | 48,191 | 18,464 | -40,775 | -39,697 | 35,979 | 72,522 | 7,248 | 62,780 | 13,525 | -145,712 | 61,887 | 34,910 | 32,861 | 28,873 | -139,127 | 41,471 | 46,145 | 23,541 | 12,275 |
Cashflow From Financing | -96.7% | 2,423 | 73,043 | -965 | -133 | 17,365 | 158,564 | 37,500 | 399 | 100 | 413 | 383 | 165,585 | 420 | 699 | 183 | 707 | 161,963 | 697 | 498 | 316 | 153 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Total revenues | $ 77,428 | $ 23,638 | $ 3,154 |
Costs and expenses: | |||
Cost of sales | 9,302 | 2,133 | 599 |
Research and development | 134,951 | 108,630 | 104,128 |
Selling, general, and administrative | 117,532 | 92,032 | 68,486 |
Total costs and expenses | 261,785 | 202,795 | 173,213 |
Loss from operations | (184,357) | (179,157) | (170,059) |
Other income (expense): | |||
Other income (expense), net | 190 | (790) | 100,000 |
Interest expense | (13,892) | (5,201) | |
Interest income | 13,945 | 4,029 | 447 |
Total other income (expense), net | 243 | (1,962) | 100,447 |
Loss before taxes | (184,114) | (181,119) | (69,612) |
Provision for income taxes | 564 | ||
Net loss | $ (184,678) | $ (181,119) | $ (69,612) |
Net loss per share, basic (in dollars per share) | $ (3.20) | $ (3.47) | $ (1.40) |
Net loss per share, diluted (in dollars per share) | $ (3.20) | $ (3.47) | $ (1.40) |
Weighted-average common shares outstanding, basic (in shares) | 57,673,128 | 52,120,701 | 49,600,294 |
Weighted-average common shares outstanding, diluted (in shares) | 57,673,128 | 52,120,701 | 49,600,294 |
Other comprehensive loss: | |||
Net Income (Loss) | $ (184,678) | $ (181,119) | $ (69,612) |
Foreign currency translation adjustment | (140) | ||
Unrealized gain (loss), net on marketable securities | 366 | (91) | (1) |
Comprehensive loss | (184,452) | (181,210) | (69,613) |
Product revenue | |||
Total revenues | 77,428 | 16,884 | 3,154 |
License revenue | |||
Total revenues | $ 0 | $ 6,754 | $ 0 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 60,081 | $ 127,677 |
Short-term investments | 215,765 | 205,611 |
Accounts receivable, net | 14,867 | 6,224 |
Inventory | 8,624 | 2,917 |
Prepaid expenses and other current assets | 8,931 | 11,807 |
Total current assets | 308,268 | 354,236 |
Property and equipment, net | 1,341 | 2,197 |
Right-of-use asset | 781 | 1,182 |
Intangible assets, net | 7,028 | 7,883 |
Restricted cash | 328 | 328 |
Other long-term assets | 14,999 | 16,655 |
Total assets | 332,745 | 382,481 |
Current liabilities: | ||
Accounts payable | 4,885 | 4,797 |
Accrued expenses and other current liabilities | 48,262 | 32,894 |
Deferred revenue | 1,286 | 1,434 |
Lease liability | 770 | 684 |
Total current liabilities | 55,203 | 39,809 |
Long-term liabilities: | ||
Deferred royalty obligation | 106,143 | 75,810 |
Lease liability, non-current | 490 | 1,260 |
Derivative liability | 1,150 | 1,340 |
Total liabilities | 162,986 | 118,219 |
Stockholders' equity: | ||
Preferred Stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022 | ||
Common stock, $0.001 par value: 120,000,000 shares authorized; 59,426,559 and 56,612,429 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 59 | 56 |
Additional paid-in capital | 1,064,302 | 974,356 |
Accumulated other comprehensive income (loss) | 134 | (92) |
Accumulated deficit | (894,736) | (710,058) |
Total stockholders' equity | 169,759 | 264,262 |
Total liabilities and stockholders' equity | $ 332,745 | $ 382,481 |